RCS - Verici Dx PLC - CEO Video Interview

Verici DxAnnouncement

15/06/2022 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220615:nRSO9685Oa&default-theme=true

RNS Number : 9685O  Verici Dx PLC  15 June 2022

Verici Dx plc

("Verici Dx" or the "Company")

 

CEO Video Interview

 

Outlining positive data from Tuteva™ clinical validation study

Test performance better than existing care "by multiple times"

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that an interview with Chief Executive, Sara
Barrington, has been published this morning highlighting the positive
performance data for Tuteva™, the Company's post-transplant blood test
focused on acute rejection. The interview can be viewed here:

 

https://www.voxmarkets.co.uk/articles/verici-dx-interview-with-ceo-sara-barrington-c2bbfd2/
(https://www.voxmarkets.co.uk/articles/verici-dx-interview-with-ceo-sara-barrington-c2bbfd2/)

 

In the interview, Sara highlights that the data from its blinded,
international, multi-centre validation study shows the superior clinical
performance of Tuteva™ compared to existing diagnostics "by multiple times"
and that the data received a very positive response at the American Transplant
Congress ("ATC") earlier this month.

 

The interview follows on from the news announced yesterday of further data
demonstrating the effectiveness of the test in providing clinicians with
actionable information to better inform the medical management of kidney
transplant patients. Yesterday's announcement can be seen here:
https://vericidx.com/tuteva-clinical-validation-study/
(https://vericidx.com/tuteva-clinical-validation-study/)

 

The positive performance data establishes a new industry standard in detection
of acute kidney transplant rejection and paves way for US commercial launch in
2022.

 

The headline result from the study was originally announced on 12 May, which
can be seen here: https://vericidx.com/positive-results-for-tuteva/
(https://vericidx.com/positive-results-for-tuteva/)

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Kailey Aliyar / Tom Salvesen

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes.  The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage.  The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology and collaboration with medical device, biopharmaceutical and data
science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKPBPCBKKQAD